Show simple item record

PARTNER/PARTNERING: BRCA positive and Triple Negative Breast Cancer Phase II poor responders sub-study to establish if post-neoadjuvant, pre-surgical addition of novel therapies improves pathological outcome at surgery

dc.contributor.authorPinilla, K
dc.contributor.authorVallier, AL
dc.contributor.authorGrybowicz, L
dc.contributor.authorQian, WD
dc.contributor.authorThomas, S
dc.contributor.authorWeiss, M
dc.contributor.authorHarvey, C
dc.contributor.authorKateb, A
dc.contributor.authorMachin, A
dc.contributor.authorDemiris, N
dc.contributor.authorWulff, J
dc.contributor.authorMcAdam, K
dc.contributor.authorHughes-Davies, L
dc.contributor.authorRoberts, A
dc.contributor.authorRoylance, R
dc.contributor.authorCopson, E
dc.contributor.authorArmstrong, Anne C
dc.contributor.authorLevitt, N
dc.contributor.authorProvenzano, E
dc.contributor.authorTischkowitz, M
dc.contributor.authorMcMurtry, E
dc.contributor.authorEarl, H
dc.contributor.authorAbraham, JE
dc.date.accessioned2020-04-22T07:25:09Z
dc.date.available2020-04-22T07:25:09Z
dc.date.issued2020en
dc.identifier.citationPeiro C, Moncada S. Substituting Angiotensin-(1-7) to Prevent Lung Damage in SARSCoV2 Infection? Circulation. 2020.en
dc.identifier.urihttp://hdl.handle.net/10541/622913
dc.language.isoenen
dc.titlePARTNER/PARTNERING: BRCA positive and Triple Negative Breast Cancer Phase II poor responders sub-study to establish if post-neoadjuvant, pre-surgical addition of novel therapies improves pathological outcome at surgeryen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentUniversity of Cambridge, Cambridgeen
dc.identifier.journalBreast Cancer Research and Treatmenten
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record